Contact Us
Drug Search Results
More Filters [+]

Carlumab

Alternative Names: carlumab, cnto-888, cnto 888, cnto888
Latest Update: 2023-06-01
Latest Update Note: PubMed Publication

Product Description

a human IgG1kappa anti-CCL2 mAb (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24928772/)

Mechanisms of Action: CCL2 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Centocor
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Carlumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Prostate Cancer|Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias

Phase 1: Hypertension|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2008-001281-86

P2

Completed

Idiopathic Pulmonary Fibrosis

2012-08-14

CR015235

P2

Completed

Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis

2012-01-01

2009-011251-48

P2

Completed

Prostate Cancer

2011-07-06

CR015907

P2

Completed

Prostate Cancer

2011-07-01

Recent News Events

Date

Type

Title

06/01/2023

PubMed

 Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis.

03/30/2023

PubMed

 Bioinformatics-integrated screening of systemic sclerosis-specific expressed markers to identify therapeutic targets.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions